RPG LIFE SCIENCES LTD. - 532983 - Announcement under Regulation 30 (LODR)-Investor Presentation
In continuation to our Letter dated September 12, 2022, please find enclosed herewith the Investor's Presentation which will be made during RPG Annual Investor Conference 2022. Kindly take the same on record. RPG LIFE SCIENCES LTD. - 532983 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 (6) read with Para A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, please find below the details of Analyst/Institutional meet(s). RPG LIFE SCIENCES LTD. - 532983 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Please find enclosed herewith intimation of loss of share certificate as received by us from Link Intime India Private Limited, our Registrar and Share Transfer Agent, being submitted to you pursuant to Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Kindly take the same on record. RPG LIFE SCIENCES LTD. - 532983 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Please find enclosed herewith intimation of loss of share certificate as received by us from Link Intime India Private Limited, our Registrar and Share Transfer Agent, being submitted to you pursuant to Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Kindly take the same on record. RPG LIFE SCIENCES LTD. - 532983 - Announcement under Regulation 30 (LODR)-Investor Presentation
Please find enclosed herewith a copy of Investor Presentation with respect to Unaudited Financial Results of the Company for the quarter ended June 30, 2022. Kindly take the same on record. RPG LIFE SCIENCES LTD. - 532983 - Announcement under Regulation 30 (LODR)-Newspaper Publication
In terms of the Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith a copy of the newspaper publications with respect to Unaudited Financial Results for the quarter ended June 30, 2022. Kindly take this information on record. Q1FY23 Quarterly Result Announced for RPG Life Sciences Ltd.
Pharmaceuticals firm RPG Life Sciences Announced Q1FY23 Result : Q1 FY23 Revenue from operations grew by 19 % YoY and 24% QoQ. PBT grew by 30% YoY and 130% QoQ. RPG Life Sciences, engaged in the manufacturing and marketing of pharmaceutical products, posted a jump in PBT by 30% YoY and by 130% QoQ for Q1 FY23. Revenue from operations at Rs 128.93 crores registered a growth of 19% YoY and a growth of 24% QoQ for Q1 FY23. The Company maintained the upward trajectory in EBITDA margin, which improved from 21.6% to 22.5% YoY Mr. Yugal Sikri, Managing Director, RPG Life Sciences Ltd. said, “In Q1 FY23, the overall performance of the Company continued to be strong despite the geo-political challenges impacting supply chain and costs. Revenue and PBT grew by 19% and 30% respectively YoY EBITDA margin retained its upward trajectory growing from 21.6% to 22.5% YoY. Domestic Formulations business has recorded a robust growth both in value and volumes - significantly and consistently better than the market. While our comprehensive life cycle management program for legacy brands is helping them register healthy growth, our new product portfolio comprising of newer and progressive segments is also witnessing an impressive uptake. We have successfully forayed into a new therapy area - Rheumatology, which is strengthening our Specialty segment. Salesforce productivity continues to register healthy upward momentum. International Formulations business has shown a robust recovery while API business continue to register growth. Our unique digital initiative, RPGServ, is having impressive traction in physician connect and engagement. Going forward, we stay committed to implementing our Transformation Agenda to grow both topline and bottomline across segments.” Result PDF RPG LIFE SCIENCES LTD. - 532983 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Please find enclosed herewith a copy of press release with respect to Unaudited Financial Results of the Company for the quarter ended June 30, 2022. Kindly take the above on record RPG LIFE SCIENCES LTD. - 532983 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Please find enclosed herewith intimation of issuance of duplicate share certificates as received by us from Link Intime India Private Limited, our Registrar and Transfer Agents, being submitted to you pursuant to Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Kindly take the same on record. RPG LIFE SCIENCES LTD. - 532983 - Unaudited Financial Results For The Quarter Ended June 30, 2022
Pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith Unaudited Financial Results for the quarter ended June 30, 2022 which were approved by the Board of Directors of the Company, at its meeting held on August 02, 2022 along with Limited Review Report issued by the Statutory Auditors of the Company. The meeting commenced at 03:00 p.m. and concluded at 06:00 p.m. Kindly take the above on your record.